Trial Profile
Phase III Study of Adjuvant Therapy With Thalidomide for Chemoembolization in Advanced Hepatocellular Carcinoma.
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Thalidomide (Primary) ; Ethiodized oil; Fluorouracil; Mitomycin; Oxaliplatin
- Indications Liver cancer
- Focus Therapeutic Use
- 20 Apr 2011 Planned End Date changed from 1 Jun 2012 to 1 Apr 2013, according to ClinicalTrials.gov.
- 20 Apr 2011 Time to progression is now a secondary endpoint not a primary endpoint and inclusion criteria, ECOG score has been changed from 1-2 to 0-2; reported by ClinicalTrials.gov.
- 01 Jul 2009 Planned end date changed from 1 Jun 2011 to 1 Jun 2012 as reported by ClinicalTrials.gov.